Tekla Life Sciences Investors Stock (NYSE:HQL)


OwnershipFinancialsChart

Previous Close

$14.74

52W Range

$11.62 - $15.90

50D Avg

$15.03

200D Avg

$14.32

Market Cap

$394.67M

Avg Vol (3M)

$67.07K

Beta

0.70

Div Yield

$2.00 (11.50%)

HQL Company Profile


Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.

Show More

Industry

Asset Management

Sector

Financial Services

Exchange

NYSE

ADR

-

Country

US

Employees

-

IPO Date

May 01, 1992

Website

HQL Performance


HQL Financial Summary


Sep 23Sep 22Sep 21
Revenue$23.52M$-103.25M$65.69M
Operating Income$22.35M$-104.60M$64.53M
Net Income$22.35M$-104.60M$64.53M
EBITDA$22.35M$-104.60M$64.53M
Basic EPS$0.83$-4.07$2.66
Diluted EPS$0.83$-4.07$2.66

Fiscal year ends in Sep 23 | Currency in USD